Abstract
In a prospective study spanning 2 years, 60 patients with grass pollen allergy were treated with either a low dose oral, a high dose oral or a subcutaneous hyposensitization regime. No significant improvement was seen in the orally treated patients whereas those on the subcutaneous hyposensitization regime demonstrated a decreased specific cutaneous reactivity, a rise in specific IgG antibodies and a reduction in symptoms. This study suggests that oral hyposensitization, even with enterosoluble grass pollen capsules, is ineffective.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Administration, Oral
-
Adolescent
-
Capsules
-
Child
-
Conjunctivitis, Allergic / therapy*
-
Delayed-Action Preparations
-
Desensitization, Immunologic*
-
Evaluation Studies as Topic
-
Female
-
Histamine Release / immunology
-
Humans
-
Immunoglobulin E / analysis
-
Immunoglobulin G / analysis
-
Immunotherapy / methods*
-
Injections, Subcutaneous
-
Intestinal Absorption
-
Male
-
Poaceae / immunology
-
Pollen / immunology*
-
Prospective Studies
-
Randomized Controlled Trials as Topic
-
Severity of Illness Index
Substances
-
Capsules
-
Delayed-Action Preparations
-
Immunoglobulin G
-
Immunoglobulin E